Quarterly Bulletin M alaysian M edic al Council 01-2008 KDN:UKP 100-3/3 Jld.2-(29) CONTENTS President’s Foreword Editorial Reflection Mediation Secretary’s Report Highlights…

1.Drug Use, Regulation,and the Law Chapter 32. Guidelines for Controlling Drug Development and Marketing Society has the right to protect itself from the damaging impact…

1. Risk-based Monitoring: What it Needs to Be Phil Doren, Ph.D., Global Vice President, Biometrics A Full-Service International CRO 2. www.SynteractHCR.com Risk-based Monitoring…

Audit’s Role in Sponsored Programs Who we are What we do Why so much focus on Sponsored Programs? What to do if an “Auditor” calls Policies related to Sponsored Programs…

Student Handbook: Making Sense of Human Subjects Research 2013 Office for the Protection of Research Subjects (OPRS) Susan L. Rose, Executive Director Jennifer Hagemann,…

Laurentian University Research Ethics Board (LUâs REB) Who are we: Contact People Jean Dragon Ph.D. (Ethics Officer) RDC Office L-313 [email protected] Phone: 675-1151-3213…

Drug Slides Ch. 3 Drug Use, Regulation, and the Law Chapter 3 Guidelines for Controlling Drug Development and Marketing Society has the right to protect itself from the damaging…

Quality Improvement & Research Donna Saxton, MHA, MPH, FACHE VP, Quality and Safety Stephanie Gaudreau, CIP IRB Administrator Session Objectives Review difference between…

Presented by: Robert Lindblad, M.D. Blake Apple Maria Campanella, B.S.N., R.N., CCRA Identifying, Reporting and Resolving Adverse Events in CTN Trials Training Outline Bob…